HCFA (Health Care Financing Administration) agrees national cover for arthritis blood filter
This article was originally published in Clinica
Executive Summary
Cypress Bioscience's blood filtering device has gained national coverage approval from the US Health Care Financing Administration (HCFA) for use in Medicare patients with severe rheumatoid arthritis who have failed to respond to anti-rheumatic drugs. This will boost the fortunes of the tiny company whose revenue is less than a $1 million a quarter.